Table 3. Characteristics of studies included for the individual and modifying effect of rs2853669 on cancer prognosis.
| First author | Publicationyear | Country | Cancertype | Sex | Follow-up | Cases | Outcomes |
|---|---|---|---|---|---|---|---|
| Individual effect of rs2853669 | |||||||
| Shen [20] | 2012 | USA | BC | F | The mean follow-up time was 8.0 years (range: 0.2–9.4 years). | 1,102 | BCSM |
| Park [21] | 2014 | Korea | GBM | F/M | > 1500 days for OS and > 800 days for PFS | 48 | OS; PFS |
| Mosrati [24] | 2015 | Sweden | GBM | F/M | > 60 months | 92 | OS |
| Mosrati [25] | 2015 | Sweden | AML | F/M | > 120 months | 226 | OS |
| Simon [17] | 2015 | Germany | GBM | F/M | The mean follow-up was 16.5+15.3 months (median: 12.0; range: 1–97) | 176 | OS |
| Spiegl-Kreinecker [15] | 2015 | Austria | GBM | F/M | > 150 months | 126 | OS |
| Batista [18] | 2016 | Portugal and Brazil | GBM | F/M | > 125 months | 164 | OS |
| Nagore [16] | 2016 | Spain | LICM | F/M | The median follow-up was 47 months (95% CI 39–56). | 300 | MSS; DFS |
| Modifying effect of rs2853669 on TERTp mutations | |||||||
| Rachakonda [8] | 2013 | Sweden | BLC | F/M | 15 years | 327 | OS; RFS |
| Park [21] | 2014 | Korea | GBM | F/M | > 1500 days for OS and > 800 days for PFS | 48 | OS; PFS |
| Hosen [22] | 2015 | Germany and Sweden | CCRCC | F/M | NA | 188 | DFS |
| Simon [17] | 2015 | Germany | GBM | F/M | The mean follow-up was 16.5+15.3 months (median: 12.0; range: 1-97) | 176 | OS |
| Spiegl-Kreinecker [15] | 2015 | Austria | GBM | F/M | > 150 months | 67 | OS |
| Batista [18] | 2016 | Portugal and Brazil | GBM | F/M | > 125 months | 504 | OS |
| Ko [11] | 2016 | Korea | HCC | F/M | > 60 months | 165 | OS; RFS |
| Nagore [16] | 2016 | Spain | LICM | F/M | The median follow-up was 47 months (95% CI 39-56). | 300 | OS; DFS |
BC, breast cancer; AML, acute myeloid leukemia; GBM, glioblastoma; LICM, localized invasive cutaneous melanoma; BLC, bladder cancer; CCRCC, clear cell renal cell carcinoma; HCC, hepatocellular carcinoma; F, female; M, male; NA, not available; BSCM, breast cancer-specific mortality; OS, overall survival; PFS, progression-free survival; MSS, melanoma-specific survival; DFS, disease-free survival; RFS, recurrence-free survival.